Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" with the regulator.

-U.S. futures for the S&P 500 and Dow Jones Industrial Average rose 0.1% and Nasdaq futures gained 0.3%. Earnings will come today from Boeing, Spotify, United Health, Procter & Gamble, Visa and PayPal ...

WASHINGTON – OpenAI CEO Sam Altman warned of a looming fraud crisis in the financial industry due to AI’s ability to mimic voices. Speaking at a Federal Reserve conference Tuesday, ...

Roche Holding AG paused some shipments of the controversial gene therapy Elevidys following a similar action by the embattled US biotechnology company that developed the treatment.